IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Akeso Biopharma Inc / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/akeso-biopharma-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso Biopharma Inc (1495016D CH)</a> is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology and other therapeutic areas. Amid the extreme market volatility, it is braving the moribund IPO market by pre-marketing a Hong Kong IPO to raise $200-300 million. <div class="content-highlight">Akesobio has strong pedigree due to a combination of credible pre-IPO investors and partnerships with leading pharma companies. The four core drug candidates which target an array of indications are AK104 (PD-1/CTLA-4), penpulimab (AK105) (PD-1), AK101 (IL-12/IL-23) and ebronucimab (AK102) (PCSK9). Overall, we believe that most of the key products have good prospects.</div>

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology and other therapeutic areas. Amid the extreme market volatility, it is braving the moribund IPO market by pre-marketing a Hong Kong IPO to raise $200-300 million. Akesobio has strong pedigree due to a combination of credible pre-IPO investors and partnerships with leading pharma companies. The four core drug candidates which target an array of indications are AK104 (PD-1/CTLA-4), penpulimab (AK105) (PD-1), AK101 (IL-12/IL-23) and ebronucimab (AK102) (PCSK9). Overall, we believe that most of the key products have good prospects.

Akesobio IPO Initiation: The Tough Get Going

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

S&amp;P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance in 2015-2016 at 2,130-2,200. The 2,346 level would make a lot of sense, however there is nothing that says we can’t be down 35% (coinciding with the 2,130-2,200 level) or more from the highs. Ultimately, COVID-19 is holding the market hostage and it likely will stay that way until the virus spread diminishes.

S&amp;P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance in 2015-2016 at 2,130-2,200. The 2,346 level would make a lot of sense, however there is nothing that says we can’t be down 35% (coinciding with the 2,130-2,200 level) or more from the highs. Ultimately, COVID-19 is holding the market hostage and it likely will stay that way until the virus spread diminishes.

S&P 500 Technical Appraisal and Support Levels

Nasdaq-100 Stock Index / Technical Analysis

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major long-term support lead us to believe an important bottom has been established. We also highlight attractive Groups and stocks within Staples, Financials, and Health Care: Large- &amp; Small-Cap Soft Drinks &amp; Bottlers, Electronic Exchanges/Markets, and Large- and Mid-Cap Biotech.

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major long-term support lead us to believe an important bottom has been established. We also highlight attractive Groups and stocks within Staples, Financials, and Health Care: Large- &amp; Small-Cap Soft Drinks &amp; Bottlers, Electronic Exchanges/Markets, and Large- and Mid-Cap Biotech.

A Bottom Has Been Established; Possible Retest?

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

U.S. Equity Strategy: Upgrading Health Care to Overweight

As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based advance. There are some developments that leave us wanting more, but we are inching toward an outright bullish outlook. In today’s report we outline our U.S. investment thesis, and highlight attractive Groups and stocks within Health Care, Materials, and Manufacturing: Biotech, Large-Cap, Aluminum, Chemicals, Diversified, and Fluid Technology &amp; Power.

As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based advance. There are some developments that leave us wanting more, but we are inching toward an outright bullish outlook. In today’s report we outline our U.S. investment thesis, and highlight attractive Groups and stocks within Health Care, Materials, and Manufacturing: Biotech, Large-Cap, Aluminum, Chemicals, Diversified, and Fluid Technology &amp; Power.

U.S. Equity Strategy: Small-Caps Testing Critical Resistance; Downgrading Communications

United States

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amgen Inc (AMGN US)

Akesobio IPO Initiation: The Tough Get Going

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...

Arun George

S&P 500 Technical Appraisal and Support Levels

S&P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance...

Vermilion Research

A Bottom Has Been Established; Possible Retest?

In today’s report we outline our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Vermilion Research

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Vermilion Research

U.S. Equity Strategy: Small-Caps Testing Critical Resistance; Downgrading Communications

As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)